MedTrace Logo

Calcium Channel Blockade in Primary Aldosteronism

NCT04179019 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-04-15

Study results available
· View outcomes & findings →

Summary

This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.

Conditions

  • Primary Aldosteronism
  • Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)

Interventions

DRUG

Amlodipine

Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Anand Vaidya, MD · Brigham and Women's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2023-12-30
Completion
2023-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04179019 on ClinicalTrials.gov